64 13.3.2 Duration of Overall Response ................................................................................. 64 13.3.3 Measurable Disease ................................................................................................ 64 13.3.4 Malignant Lymph Nodes ........................................................................................ 64 13.3.5 Non-Measurable Disease ........................................................................................ 64 9 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 13.3.6 Evaluable Disease ................................................................................................... 65 13.3.7 Target Lesions .........................................................................................................